LATEST ARTICLES

8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities...

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s...

Topline data anticipated in October 2020 as previously guided ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody...

Ohio State Conducts First Gene Therapy Clinical Trial For Huntington’s Disease

COLUMBUS, Ohio – In a worldwide first, surgeons at The Ohio State University Wexner Medical Center have treated two patients with Huntington’s disease using a novel...

Novel pathology could improve diagnosis and treatment of Huntington’s and other...

Bristol scientists have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington’s disease. The article, published in Brain Pathology, describes how SAFB1...

Changing jobs: converting other cell types into neurons

Because HD causes a loss of neurons in the brain, some researchers are exploring ways to replace them. Working with HD mice, scientists recently...

uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial...

~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE),...